MetaCap

LB Pharmaceuticals (LBRX) vs Silence Therapeutics Plc American Depository Share (SLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Silence Therapeutics Plc American Depository Share (SLN) has outperformed LB Pharmaceuticals (LBRX) over the past year, gaining 213.9% versus a gain of 153.4%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LBRX+153.42%SLN+213.95%
+235%+95%-45%
Nov 21, 20251 yearNov 20, 2026
LBRX+131.25%SLN+339.25%
+357%+164%-29%
Sep 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LBRX versus SLN key metrics
MetricLBRXSLN
Share price$38.85$19.81
Market cap$1.26B$1.23B
1-day change-2.97%0.00%
YTD return+74.53%+225.82%
1-year return+153.42%+213.95%
5-year return—-9.95%
EPS (TTM)$-1.12$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$559.00K
Revenue growth (YoY)—-98.71%
Net income (latest FY)$-25.20M$-88.61M
Gross margin—61.54%
Operating margin—-16292.84%
Net margin—-15851.88%
52-week high$50.16$19.87
52-week low$15.55$4.19
Distance from 52-week high-22.55%-0.28%
Analyst consensusstrong_buyhold
Avg. price target upside+49.29%-0.30%
Average volume373.16K2.41M
Shares outstanding32.36M62.20M
Employees6288
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLN has outperformed LBRX by 60.5 percentage points over the past year.

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

About Silence Therapeutics Plc American Depository Share

SLN stock →

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

LBRX vs SLN FAQ

Which is bigger, LB Pharmaceuticals or Silence Therapeutics Plc American Depository Share?

LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.23B for Silence Therapeutics Plc American Depository Share (SLN).

Which stock has performed better over the past year, LBRX or SLN?

SLN returned +213.95% over the past 12 months, compared with +153.42% for LBRX (price return, excluding dividends). Past performance does not predict future results.

Are LB Pharmaceuticals and Silence Therapeutics Plc American Depository Share in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons